Picture of Ipsen SA logo

IPN — Ipsen SA Share Price

0.000.00%
fr flag iconLast trade - 00:00
HealthcareAdventurousLarge CapSuper Stock

Momentum

Relative Strength (%)
1m-1.89%
3m
6m
1yr
Volume Change (%)
10d/3m
Price vs... (%)
52w High-6.81%
50d MA
200d MA

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Financial Summary

Year End 31st DecUnit201620172018201920202021E2022ECAGR / Avg
Total Revenue€m1,671.12,011.82,348.42,692.82,686.22,886.282,919.2312.06%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%+9.45+25.46+19.6-4.01+69.38+5.66-4.71n/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Latest News & Insights for IPN

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202131st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2021 / 2022

Blurred out image of Ipsen SA EPS forecast chart

Profile Summary

Ipsen SA is a France-based biopharmaceutical group specialized in specialty care. The Company operates globally through two segments: Specialty Care and Consumer Healthcare. In Specialty Care, the Company is focused on various therapeutic areas, including oncology, neurosciences and rare diseases. Its oncology portfolio includes Somatuline, Decapeptyl, Cabometyx and Onivyde. Its neuroscience portfolio includes Dysport, and in rare diseases key products are NutropinAq and Increlex. Its primary care portfolio includes Smecta, Forlax, Fortrans, Eziclen, and Tanakan. In oncology Ipsen focuses on a number of disease areas, which include neuroendocrine tumors, renal cell carcinoma, hepatocellular carcinoma and pancreatic cancer. In addition, the Company has specialism in neurotoxin research and operates three research and development centers located in France, the United Kingdom and the United States.

Directors

Last Annual
December 31st, 2020
Last Interim
June 30th, 2021
Incorporated
July 28th, 1998
Public Since
December 6th, 2005
No. of Employees
5,703
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
fr flag iconEuronext - Paris
Shares in Issue
82,964,839

IPN Share Price Performance

Latest News for IPN

Upcoming Events for IPN

Full Year 2021 Ipsen SA Earnings Release

Q1 2022 Ipsen SA Corporate Sales Release

Ipsen SA Annual Shareholders Meeting

Similar to IPN

Picture of AB Science SA logo

AB Science SA

fr flag iconEuronext - Paris

Picture of Advicenne SA logo

Advicenne SA

fr flag iconEuronext - Paris

Picture of Biocorp Production SA logo

Biocorp Production SA

fr flag iconEuronext - Paris

Picture of Boiron SA logo

Boiron SA

fr flag iconEuronext - Paris

Picture of DBV Technologies SA logo

DBV Technologies SA

fr flag iconEuronext - Paris

FAQ

Or unlock with your email

Or unlock with your email